Already have an account?


Login with an existing Projects In Knowledge account
New to Projects In Knowledge?


Register today to customize your experience.
Log In
Don't have an account yet? Click here to register



Register for Free
Already have an account? Click here to log in



Enter your current email address.  Your email address will be your user name, and where you will receive confirmation of this registration.



Forgot Password

Please Enter your email address.




  Terms & Conditions                                                                                                                                     

Privacy Policy

Projects In Knowledge is committed to protecting the privacy and confidentiality of visitors to our Web site. While Projects In Knowledge does not require that you provide us with personally identifiable information in order to visit our Web site, please note that in order to participate in the continuing medical education activities that we provide, it will be necessary for you to register with us and provide this information.

About this Privacy Policy
www.projectsinknowledge.com is our Web site for physicians and allied health care professionals, although it is open to non-professionals as well. The purpose of projectsinknowledge.com is to provide continuing medical education for healthcare professionals, and is intended for use only by a licensed healthcare professional.

Projects In Knowledge is the name we use to refer to our entire company, even though our formal corporate name is Projects In Knowledge, Inc. When we refer to ourselves as "we" or "Projects In Knowledge," we mean our company, Projects In Knowledge, Inc., including any subsidiary that we control (for example, a subsidiary that we own). We may share information among our subsidiaries that we own or control, but it is always protected under the terms of this privacy policy.

This privacy policy applies only to the Projects In Knowledge Web site. You should read the privacy policy at each Web site that you visit after you leave our site. We are not responsible for how other Web sites treat your privacy, once you leave the Projects In Knowledge site.

Privacy Policy Changes
If we change our privacy policy, we will post those changes on this page. Users should check this policy to keep abreast of any changes.

Information We Collect
In this section of our privacy policy, we discuss the different types of information we may collect about you, and the ways in which we collect them.

Information We Collect from Unregistered Visitors
Visitors to our Web site can access the Web site's home page and browse the site without disclosing any personally identifiable information. We do track information provided to us by your browser, including the Web site you came from (known as the "referring URL"), the type of browser you use, the time and date of access, and other information that does not personally identify you.

Information We Collect When You Register
Customers registering on our Web site for continuing medical education activities we provide are asked to provide us with identifying information, such as name, contact information, and other identifying information. On our registration screens, we clearly label which information is required for registration, and which information is optional and may be given at your discretion.

On our registration screens you will also find a “Burning Question” field. Submission of a “Burning Question” is completely voluntary. By submitting a “Burning Question,” you grant Projects In Knowledge the right to share it with faculty to consider as they prepare their continuing medical education presentations.

Listserves
When you are using a listserve—or member-only discussion board— on our Web site, you are posting a message and your user name, which is available for all registered members to see. You should not post any information to our listserves you want to keep private. It is a condition of our Web site that when participating in a listserve, you do not:

  • Restrict or inhibit any other user from using the listserve
  • Post or transmit any unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane or indecent information of any kind, including, without limitation, any transmission constituting or encouraging conduct that would constitute a criminal offense, give rise to civil liability or otherwise violate any local, state, national or foreign law
  • Post or transmit any information, software or other material which violates or infringes upon the rights of others, including material which constitutes an invasion of privacy or infringement of publicity rights or which is protected by copyright, trademark or other proprietary right, or derivative works thereof, without first obtaining permission from the owner or right holder
  • Post or transmit any information, software or other material which contains a virus or other harmful component
  • Post, or transmit, or in any way exploit any information, software or other material for commercial purposes which contains advertising, promotions or marketing

By sending a message through the listserve, you grant Projects In Knowledge the non-exclusive right and license to display, copy, publish, distribute, transmit, print, and use such information. Projects In Knowledge reserves the right to terminate your access to, and use of, the listserve if you do not abide by these conditions.

Use of Cookies
Cookies are a technology used by the Projects In Knowledge Web site to identify a user as the user moves through the Web site. Your browser allows us to place some information on your computer's hard drive that identifies the computer you are using. We use cookies to track your usage throughout our Web site.

Your Web browser can be set to allow you to control whether you will accept cookies, reject cookies, or to notify you each time a cookie is sent to you. If your browser is set to reject cookies, Web sites that are cookie-enabled will not recognize you when you return to the Web site, and some Web site functionality may be lost. The Help section of your browser will tell you how to prevent your browser from accepting cookies.

Although cookies do not normally contain personally identifiable information, if you are a registered user we may associate your registration information with cookies our Web site places on your computer's hard drive. Associating a cookie with your registration data allows us to offer increased personalization and functionality. For example, you can elect to have our Web site "remember" you and bypass the registration process each time you register for one of our educational activities. Without cookies, this functionality would not be possible. Projects In Knowledge does not currently employ cookies for this use, but is considering it to make our registration processes more efficient for you.

Children's Privacy
Projects In Knowledge's Web site is designed and intended for use by adults, and is not intended for, nor designed to be used by children under the age of 18, or any other unlicensed, untrained individuals. We do not collect personally identifiable information from any person we know is a child under the age of 18.

Uses We Make of Information
In this section of our privacy policy, we identify the ways we may use information about you that we have collected.

Aggregate Data
We create aggregate data about visitors to our Web site for activity development and improvement. We also use it for market analysis. We may provide information from our Web site in aggregate form, with identifying information removed, to third parties. For example, we may tell a third party what percentage of our registered users reside in a particular geographical area. When aggregated information is provided, we pool it from many individual records and strip it of any data that could be used to identify an individual before it is used. Any third party that receives aggregated data must agree not to attempt to re-identify the people it belongs to. Projects In Knowledge does not sell any user data to any third party for commercial purposes.

Third Parties
In addition to aggregate information (discussed previously), we may share some kinds of information with third parties as described below.

  • Business Transfers: If we transfer a business unit (such as a subsidiary) or an asset (such as a Web site) to another company, we will require them to honor the applicable terms of this privacy policy.

Protection of Information
In this section of our privacy policy, we discuss the security measures we take to protect information that we have collected about you.

General Policies
We have implemented technology and security policies, rules and other measures to protect the personal data that we have under our control from unauthorized access, improper use, alteration, unlawful or accidental destruction, and accidental loss. We also protect your information by requiring that all our employees and others who have access to or are associated with the processing of your data respect your confidentiality. In addition, we have appropriate security measures in place in our physical facilities to protect against the loss or misuse of information at our site that we have collected from you.

Projects In Knowledge Employees
Projects In Knowledge employees are required to keep customer information private, as a condition of their employment with the company. Only selected, authorized Projects In Knowledge employees are permitted to access your registration information.
Employees are required to sign a confidentiality agreement. All employees and contractors must abide by our privacy policy, and those who violate that policy are subject to disciplinary action, up to and including termination of their employment and legal action.

Privacy Questions or Concerns about Our Web Site
For privacy questions or concerns about the Projects In Knowledge Web site, please contact privacy@projectsinknowledge.com.

Revision date: This policy was last updated on September 30, 2003.



New and Noteworthy


  • Heart Failure — Heart Failure: Putting it Into Practice, by the Book – Webcast
  • From late August to mid-November, heart failure treatment made headlines, dominating the European Society of Cardiology, the Heart Failure Society of America and, finally, the American Heart Association meetings. In this exclusive video, Mary Norine Walsh, MD, reviews the breakthrough findings and puts them ... more >>
    P. Peck,
  • Ovarian Cancer — Case Study: Diagnosis and Treatment of a Patient With High-Grade, BRCA Wild-Type Ovarian Cancer – @Point of Care Chapter
  • Initial treatment of high-grade, BRCA wild-type ovarian cancer is typically cytoreduction followed by platinum-based chemotherapy with or without bevacizumab treatment and maintenance. The improvement in progression-free survival in patients who receive maintenance treatment following first-line therapy is a ... more >>
    L. Randall, MD, MAS
  • Breast Cancer — Case Study: Management of HR-Positive/HER2-Negative Advanced/Metastatic Breast Cancer for a Patient Whose Disease Has Progressed on an Endocrine-Based Regimen – @Point of Care Chapter
  • The majority of breast cancers are hormone receptor (HR) positive/human epidermal growth factor receptor 2 (HER2) negative. Of the many subtypes of breast cancer, invasive lobular carcinoma (ILC) is the second most prevalent, and recent studies have shown PIK3CA mutations are highly prevalent in ILC. Join ... more >>
    O. Metzger, MD
  • Metastatic Melanoma — Checkpoint Inhibitor Therapy for Stage IIIC Resected Melanoma – @Point of Care Chapter
  • This case study involves a patient with cutaneous melanoma presenting with high-risk features and illustrates how the disease is classified under the current 8th edition of the American Joint Committee on Cancer staging system. As treatment options for this patient are considered, the value of adjuvant ... more >>
    J. Mehnert, MD
  • Multiple Sclerosis — Implementing Early Treatment in A Newly Diagnosed PPMS Patient – Webcast
  • Patients with primary progressive multiple sclerosis (PPMS) have a disease course with disability that slowly worsens from the very beginning and occurs in the absence of acute attacks. Unfortunately, until recently, no effective treatments were available for these patients. This case illustrates the ... more >>
    J. Bowen, MD
  • Asthma — Case Study: Management of a Patient With Severe Eosinophilic Asthma – Case Study
  • Severe asthma may remain uncontrolled with inhaled corticosteroids and a long-acting bronchodilator, despite optimal treatment and good adherence, and management often requires use of periodic or maintenance oral corticosteroids. Type 2 inflammation, characterized by the presence of interleukin (IL)-4, IL-5, ... more >>
    J. Corren, MD
  • Metastatic Melanoma — Checkpoint Inhibitor Therapy for Newly Diagnosed Stage IV Melanoma – Case Study
  • Immunotherapy with immune checkpoint inhibitors is the current standard of care for the first-line treatment of metastatic melanoma. Combination immunotherapy with an anti-CTLA-4 agent and an anti-PD-1 agent can yield improved outcomes, but comes with the risk of increased grade 3/4 treatment-related adverse ... more >>
    A. Pavlick, DO, MBA
  • Cystic Fibrosis — Worsening Sinus Symptoms Linked to Pulmonary Declines in Cystic Fibrosis – BreakingMED
  • Understanding triggers for pulmonary exacerbations is key to management of cystic fibrosis. In this report, researchers suggest a temporal link between rhinosinusitis symptoms and pulmonary exacerbations and note the importance of SNOT-22 test and CF quality of life questionnaire.
    A. Brixey, MD
  • Hepatocellular Carcinoma — Immuno-Oncology: Hepatocellular Carcinoma – @Point of Care Chapter
  • The checkpoint inhibitors nivolumab and pembrolizumab have each received accelerated approval for the treatment of patients with hepatocellular carcinoma (HCC) following sorafenib. Furthermore, numerous studies of combination therapy have reported promising results. Although confirmatory trials continue, ... more >>
    J. Harding, MD
  • Heart Failure — Optimizing Treatment for a Patient With Hypertension and HFrEF – Case Study
  • Patients with heart failure with reduced ejection fraction should be managed using recent clinical trial outcomes and guideline-directed medical therapy (GDMT), which include agents that block the renin-angiotensin-aldosterone system. This case illustrates the real-life clinical scenario of a patient who ... more >>
    K. Ferdinand, MD
  • State of the Science: Multiple Sclerosis Innovations
  • State of the Science: Multiple Sclerosis Innovations provides comprehensive and up-to-date best practices in multiple sclerosis management. This includes innovative webcasts derived from major scientific conferences synthesized for the practicing clinician, interactive practice-based cases, and articles from ... more >>
    A. Cross, MD
    P. Peck, Editor-in-Chief
  • Master Class: Chronic Lymphocytic Leukemia
  • Master Class: Chronic Lymphocytic Leukemia (CLL) is designed to highlight relevant, practical advances in the treatment of CLL using a modular structure to provide an in-depth review of best practices with multiple complementary activities, including video webcasts with expert clinical specialists, case ... more >>
    B. Cheson, MD, FACP, FAAAS
  • The Art & Science of Heart Failure Management
  • The Art & Science of Heart Failure Management is designed to provide new information based on breaking medical news, new data presented at medical meetings, and case studies on current and emerging management strategies on the most up-to-date evidence-based medicine and clinical trial results in heart failure ... more >>
    J. Udelson, MD
  • Pulmonology Mastery in COPD
  • Pulmonology Mastery in COPD is designed to provide new information based on breaking medical news, new data presented at medical meetings, and case studies on current and emerging management strategies on the most up-to-date evidence-based medicine and clinical trial results in COPD. The curriculum includes ... more >>
    B. Make, MD
  • Mastery of Medicine in Diabetes Management
  • Mastery of Medicine in Diabetes Management is designed to provide new information based on breaking medical news, new data presented at medical meetings, and case studies on current and emerging management strategies on the most up-to-date evidence-based medicine and clinical trial results in diabetes ... more >>
    V. Fonseca, MD, FRCP
  • Clinical Context: Stroke Prevention in Atrial Fibrilation
  • Clinical Context: Stroke Prevention in
    Atrial Fibrillation
    is designed to provide up-to-date information on patient identification, risk factors, and current and emerging treatments and best practices in the management of atrial fibrillation.

    The curriculum includes:
    • 6 case studies
    • MedPage Today meeting
    ...
    more >>
    C. Yancy, MD, MSc
  • Hematology Mastery in Multiple Myeloma
  • Hematology Mastery in Multiple Myeloma is designed to provide new information based on breaking medical news, new data presented at medical meetings, and case studies on current and emerging management strategies on the most up-to-date evidence-based medicine and clinical trial results in multiple myeloma. ... more >>
    N. Raje, MD
  • Rheumatology Mastery in Rheumatoid Arthritis
  • Rheumatology Mastery in Rheumatoid Arthritis is designed to provide new information based on breaking medical news, new data presented at medical meetings, and case studies on current and emerging management strategies on the most up-to-date evidence-based medicine and clinical trial results in rheumatoid ... more >>
    M. Husni, MD, MPH
  • Rheumatology Mastery In Ankylosing Spondylitis
  • Rheumatology Mastery in Ankylosing Spondylitis is designed to provide new information based on breaking medical news, new data presented at medical meetings, and case studies on current and emerging management strategies on the most up-to-date evidence-based medicine and clinical trial results in ankylosing ... more >>
    J. Reveille, MD
  • Neurology Mastery in Multiple Sclerosis
  • Neurology Mastery in Multiple Sclerosis is designed to provide new information based on breaking medical news, new data presented at medical meetings, and case studies on current and emerging management strategies on the most up-to-date evidence-based medicine and clinical trial results in multiple sclerosis. ... more >>
    J. Bowen, MD
  • Ovarian Cancer @Point of Care
  • Ovarian cancer is often advanced at the time of diagnosis. Although most patients respond to initial treatment, relapse is common. With the approval of new therapies and better biomarkers of response, health outcomes for women with advanced ovarian cancer have improved significantly.
    B. Monk, MD, FACS, FACOG
  • Pulmonary Arterial Hypertension @Point of Care
  • Pulmonary arterial hypertension (PAH) is a rare disorder associated with significant morbidity and mortality. Three PAH treatment pathways or targets have been identified—the endothelin pathway, the nitric oxide pathway, and the prostacyclin pathway. In 1995 the FDA approved the first treatment specifically ... more >>
    R. Channick, MD
  • Bipolar Disorder @Point of Care
  • Bipolar disorder is a common mental illness that can have a devastating impact on people’s lives without effective treatment. Important developments in the understanding of bipolar disorder and its treatment have occurred in the past few years, with several new medications and formulations developed and ... more >>
    M. Thase, MD
  • Classical Hodgkin Lymphoma @Point of Care
  • Classical Hodgkin lymphoma (CHL) has a high cure rate with available therapies - nearly 90% - yet advances continue to be made to individualize therapy, minimize the risk of late toxicity, and expand therapeutic options. Current first-line treatment strategies for patients with early- and advanced-stage CHL ... more >>
    C. Moskowitz, MD
  • Nontuberculous Mycobacterial Lung Disease @Point of Care
  • Nontuberculous mycobacterial (NTM) lung disease, a condition of progressive lung damage caused by mycobacterial species other than those that cause tuberculosis or leprosy, is occurring with increasing frequency in the United States. Characterized by difficulties in diagnosis, non-FDA-approved treatment ... more >>
    N. Schluger, MD
  • Heart Failure @Point of Care
  • Heart failure is a significant health burden and, with increasing comorbidities and the aging of the population, this burden is likely to worsen especially in certain populations. Guideline-directed medical therapies have been shown to reduce morbidity and mortality in patients with heart failure, but are ... more >>
    G. Fonarow, MD
  • Alzheimer's Disease @Point of Care
  • This @Point of Care is a comprehensive, continually updated resource developed to enhance compliance to established clinical guidelines to improve screening and timely diagnosis of Alzheimer’s disease (AD) and to support current best practices of managing the symptoms of AD.
    R. Turner, MD, PhD
  • Atopic Dermatitis @Point of Care
  • Atopic dermatitis (AD) is a common inflammatory skin disease that affects both children and adults, and recent advances in the understanding of the immune and inflammatory processes involved in AD pathogenesis have led to the development and approval of novel therapies for the treatment of this disease. With ... more >>
    L. Eichenfield, M.D.
  • Hepatocellular Carcinoma @Point of Care
  • This @Point of Care provides a comprehensive, continually updated resource to the clinical care team with relevant and current evidence-based medicine and clinical trial data for approved and emerging therapies to help tailor treatment based on patient characteristics in order to improve the management of ... more >>
    G. Abou-Alfa, MD, MBA
  • Metastatic Melanoma — Checkpoint Inhibitor Therapy for Newly Diagnosed Stage IV Melanoma – Case Study
  • Immunotherapy with immune checkpoint inhibitors is the current standard of care for the first-line treatment of metastatic melanoma. Combination immunotherapy with an anti-CTLA-4 agent and an anti-PD-1 agent can yield improved outcomes, but comes with the risk of increased grade 3/4 treatment-related adverse ... more >>
    A. Pavlick, DO, MBA
  • Cystic Fibrosis — Worsening Sinus Symptoms Linked to Pulmonary Declines in Cystic Fibrosis – BreakingMED
  • Understanding triggers for pulmonary exacerbations is key to management of cystic fibrosis. In this report, researchers suggest a temporal link between rhinosinusitis symptoms and pulmonary exacerbations and note the importance of SNOT-22 test and CF quality of life questionnaire.
    A. Brixey, MD
  • Diabetes — Ask the Experts: Optimal Use of Antihyperglycemic Therapies to Prevent Cardiovascular Events, Renal Complications, and Mortality in Persons with Type 2 Diabetes Module 2: Cardiovascular Disease and Diabetes – Webcast
  • Over the past decade, many new treatment options for type II diabetes mellitus (T2DM) have been developed and approved. Recent trials have shown that two newer classes of agents, the SGLT-2 inhibitors and the GLP-1 receptor agonists, can improve cardiovascular outcomes. In this activity, Drs. Vivian Fonseca ... more >>
    V. Fonseca, MD, FRCP
  • Diabetes — Ask the Experts: Optimal Use of Antihyperglycemic Therapies to Prevent Cardiovascular Events, Renal Complications, and Mortality in Persons with Type 2 Diabetes Module 3: Renal Complications and Diabetes – Webcast
  • Over the past decade, many new treatment options for type II diabetes mellitus (T2DM) have been developed and approved. Recent trials have shown that the SGLT-2 inhibitors can improve both cardiovascular and renal outcomes. In this activity, Drs. Vivian Fonseca and Yehuda Handelsman will look at clinical ... more >>
    V. Fonseca, MD, FRCP
  • Diabetes — Ask the Experts: Optimal Use of Antihyperglycemic Therapies to Prevent Cardiovascular Events, Renal Complications, and Mortality in Persons With Type 2 Diabetes Module 1: State of the Science and Overview of New Guideline Recommendations – Webcast
  • Patients with type II diabetes mellitus (T2DM) often have significant comorbidities, such as cardiovascular disease or chronic kidney disease. Recent advances in the understanding of the mechanisms leading to T2DM have resulted in the approval of new classes of agents that specifically target underlying ... more >>
    V. Fonseca, MD, FRCP
  • Psoriasis — Switching Between Biologic Therapies Provides Longer Duration of Therapy for Psoriasis – BreakingMED
  • Switching between biologic therapies can help psoriasis patients achieve better disease control. This article takes a look at the reasons that patients need to switch and the best strategies for determining choosing another biologic.
    V. Abramson, MD
  • Psoriasis — Apremilast Added to Biologic Therapy Effective for Severe Psoriasis, Psoriatic Arthritis – BreakingMED
  • Treatment of severe psoriasis is often challenging and often requires more than monotherapy, but there is scant research on the efficacy of combination regimens. Two papers reviewed in this report offer real world data on combination therapy as well as a review of outcomes for patients with severe psoriasis ... more >>
    V. Abramson, MD
  • Ovarian Cancer — ESMO: Risk of Ovarian Ca Progression Cut with PARP Inhibitor – BreakingMED
  • The PARP-inhibitor nariparib gained FDA approval in October 2019 for the treatment of women with advanced ovarian, fallopian tube, or primary peritoneal cancer with HRD-positive status. This article discusses the PRIMA study presented at the European Society for Medical Oncology, which showed the efficacy of ... more >>
    V. Abramson, MD
  • Asthma — Ask the Experts: Treatment Options for Asthma—All Severities Considered – Webcast
  • Asthma is a heterogeneous disease with multiple underlying mechanisms that produce common clinical symptoms, which can make the diagnosis and treatment of this disease difficult. Asthma can be categorized based on clinical characteristics and phenotypes, and recent years have seen the development of several ... more >>
    D. Ledford, MD
    W. Soong, MD
  • COPD — COPD Intervention Ineffective – BreakingMED
  • In an unexpected twist, a single-site randomized clinical trial found that a program designed to provide transitional care and long-term self-management support to patients hospitalized with chronic obstructive pulmonary disease (COPD) was largely ineffective, according to researchers from Johns Hopkins ... more >>
    A. Brixey, MD
  • Asthma — Case Study: Management of a Patient With Severe Eosinophilic Asthma – Case Study
  • Severe asthma may remain uncontrolled with inhaled corticosteroids and a long-acting bronchodilator, despite optimal treatment and good adherence, and management often requires use of periodic or maintenance oral corticosteroids. Type 2 inflammation, characterized by the presence of interleukin (IL)-4, IL-5, ... more >>
    J. Corren, MD
  • Metastatic Melanoma — Checkpoint Inhibitor Therapy for Newly Diagnosed Stage IV Melanoma – Case Study
  • Immunotherapy with immune checkpoint inhibitors is the current standard of care for the first-line treatment of metastatic melanoma. Combination immunotherapy with an anti-CTLA-4 agent and an anti-PD-1 agent can yield improved outcomes, but comes with the risk of increased grade 3/4 treatment-related adverse ... more >>
    A. Pavlick, DO, MBA
  • Heart Failure — Optimizing Treatment for a Patient With Hypertension and HFrEF – Case Study
  • Patients with heart failure with reduced ejection fraction should be managed using recent clinical trial outcomes and guideline-directed medical therapy (GDMT), which include agents that block the renin-angiotensin-aldosterone system. This case illustrates the real-life clinical scenario of a patient who ... more >>
    K. Ferdinand, MD
  • Multiple Sclerosis — Managing RRMS Patient who Converted to SPMS – Case Study
  • This case illustrates the management of a patient who progresses from clinically isolated syndrome to relapsing multiple sclerosis (MS) and, eventually, secondary progressive MS (SPMS). It highlights treatment considerations for each stage of disease, with attention to the options that have been approved in ... more >>
    P. Coyle, MD
  • Multiple Sclerosis — Managing Highly Active Disease in an RRMS Patient with Worsening on Initial Treatment – Case Study
  • This case illustrates the treatment strategy employed for a RRMS patient who has high MS disease activity despite adherence to first-line injectable disease-modifying therapy. It highlights switching strategies that can be considered for such patients, and reviews safety and efficacy data for approved high- ... more >>
    P. Repovic, MD
  • Asthma — Case Study: Biologic Therapy for Allergic Asthma – Case Study
  • For patients with severe allergic asthma who are not adequately controlled with inhaler therapy, it may be necessary to consider the addition of biologic therapy. Choosing among the available biologic therapies involves taking into account the patient's asthma endotype based on biomarkers such as eosinophil ... more >>
    E. DiMango, MD
  • Multiple Sclerosis — RRMS Patient with Active On-Treatment Disease Considering a Switch to a Selective Oral S1P Inhibitor – Case Study
  • In this case, the diagnosis and initial treatment of a patient with relapsing multiple sclerosis (MS) is reviewed. This illustrates the considerations that occur when a patient has a clinical relapse while on disease-modifying therapy and highlights available and emerging oral therapies for the treatment of ... more >>
    C. Azevedo, MD, MPH
  • Multiple Sclerosis — Case Study: Misdiagnosis in MS – Case Study
  • The 2017 revisions to the McDonald criteria have refined the diagnosis of multiple sclerosis (MS). However, these criteria must only be applied to patients with symptoms typical of demyelination. In addition, there must be "no better explanation." This case follows the skillful navigation of diagnosis in a 56 ... more >>
    A. Solomon, MD
  • Multiple Sclerosis — Risk-Averse RRMS Patient With a Preference for an Oral DMT – Case Study
  • This case demonstrates the real-life clinical scenario of a patient with relapsing remitting multiple sclerosis (RRMS) who has a clinical relapse on his first disease-modifying therapy. It illustrates considerations when switching medications, including patient preference for therapeutic delivery, and ... more >>
    J. Bowen, MD
  • Multiple Sclerosis — Case Study: Patient With Secondary-Progressive MS and Active Disease – Case Study
  • This case study follows a 39-year-old man who developed relapsing-remitting multiple sclerosis (MS) when he was 34. He is being treated with an oral agent for relapsing MS; however he has since advanced to secondary-progressive MS (SPMS) and shows signs of active disease radiographically. New treatment ... more >>
    E. Williamson, MD